Kanghong Pharmaceutical announced that Kanghong Biotech, a wholly-owned subsidiary of the company, recently received a Langmu drug registration/marketing license issued by the Food and Drug Administration of the Guyanese Government, indicating that the product has obtained market entry into Guyana and can be used to treat indications such as wet age-related macular degeneration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.